Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

JHL Biotech Offers Selexis's Technology for Biologics Development

publication date: Dec 3, 2013
JHL Biotech of Taiwan struck a non-exclusive deal with Switzerland’s Selexis SA to offer the latter company’s mammalian cell line technology. The agreement will allow JHL to provide its clients with complete biologic process development and cGMP manufacturing services. JHL is building a commercial-scale biologic manufacturing facility in Wuhan, which it says will have the largest capacity in China. The company’s goal is to provide China and Asia with high-quality, low-cost biologic drugs. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital